Eli Lilly and Co (NYSE:LLY)

140.83
Delayed Data
As of Feb 19
 -0.18 / -0.13%
Today’s Change
101.36
Today|||52-Week Range
147.87
+7.15%
Year-to-Date
Better Buy: Vertex Pharmaceuticals vs. Incyte
Feb 19 / MotleyFool.com - Paid Partner Content
Will Eczema Drug Dupixent Transform Sanofi?
Feb 13 / MotleyFool.com - Paid Partner Content
Is Viking Therapeutics' Stock a Buy?
Feb 18 / MotleyFool.com - Paid Partner Content
Eli Lilly and Incyte Record Another Positive Clinical Trial for Olumiant Works in Eczema
Feb 12 / MotleyFool.com - Paid Partner Content
Better Buy: AbbVie vs. Eli Lilly
Feb 18 / MotleyFool.com - Paid Partner Content
A Double Failure of Alzheimer's Drugs
Feb 10 / MotleyFool.com - Paid Partner Content
Could This Cancer Drug Developer’s Stock Make You Rich?
Feb 14 / MotleyFool.com - Paid Partner Content
Stock Market News: Coronavirus Hits NIO; Lilly Suffers Alzheimer's Defeat
Feb 10 / MotleyFool.com - Paid Partner Content
How Incyte Beat Wall Street Estimates in Q4
Feb 13 / MotleyFool.com - Paid Partner Content
3 Canadian Biotechs to Consider Buying Today
Feb 07 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close141.01
Today’s open141.62
Day’s range140.36 - 141.84
Volume3,082,771
Average volume (3 months)3,378,182
Market cap$135.4B
Data as of 6:30pm ET, 02/19/2020

Growth & Valuation

Earnings growth (last year)--
Earnings growth (this year)+12.33%
Earnings growth (next 5 years)+11.50%
Revenue growth (last year)--
P/E ratio31.3
Price/Sales5.51
Price/Book--

Competitors

 Today’s
change
Today’s
% change
ABBVAbbVie+0.53+0.57%
AZNAstraZeneca+0.20+0.41%
SNYSanofi-0.43-0.84%
NVONovo Nordisk+0.05+0.08%
Data as of 6:30pm ET, 02/19/2020

Financials

Next reporting dateApril 23, 2020
EPS forecast (this quarter)$1.44
Annual revenue (last year)$22.3B
Annual profit (last year)$8.3B
Net profit margin20.78%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Major
No executives to display
Corporate headquarters
Indianapolis, Indiana

Forecasts